Search 33,000+ CME courses
Back

American College of Preventive Medicine

  • Analgesics, Opioid
  • Drug Overdose
  • Marijuana Use
  • Naloxone
  • Opiate Overdose

The Impact of Naloxone Coprescribing Mandates on Opioid-Involved Overdose Deaths

ntroduction Since 2017, a total of 10 states have mandated naloxone coprescribing intended to prevent fatal opioid overdoses. This study aims to assess the association between naloxone coprescribing/offering mandates and opioid-involved overdose deaths on the basis of the opioid type. Methods Data on overdose deaths from 1999 to 2020 came from the National Center for Health Statistics CDC WONDER Online Database. This study examined deaths stratified by illicit/synthetic opioids and prescription/treatment opioids. Difference-in-difference negative binomial regression models estimated average marginal effects and 95% CIs. Covariates included opioid dispensing rate, Good Samaritan law, pharmacy-based naloxone access law, mandatory use of prescription drug monitoring program, and recreational cannabis dispensaries. Data collection and analysis were conducted in 2022. Results Ten states implemented naloxone coprescribing/offering mandates during the period. Coprescribing/offering mandates significantly reduced the number of prescription/treatment overdose deaths by 8.61 per state per quarter (95% CI= 15.13, 2.09), a 16% reduction from the counterfactual estimates. Coprescribing/offering mandates did not significantly impact illicit/synthetic overdose deaths (average marginal effect=0.32; 95% CI= 18.27, 18.91). Conclusions Coprescribing/offering mandates prevent overdose deaths for its target population, individuals using prescription/treatment opioids. These mandates do not appear to impact populations using illicit/synthetic opioids; thus, expanded efforts are needed to reach these individuals.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

This is a journal-based activity. Credit is earned after completing the required reading and assessment; the amount shown is the provider-reported available credit.

AMA PRA Category 1 Credit™Up to 1 credit

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Pricing

Paid

This provider typically $35

See fees on ajpmonline.org

Listed by the provider

  • Journal-based
  • Credit · Up to 1 credit
  • Paid · this provider typically $35
  • Released
    Jun 23, 2024
  • Last day to claim credit
    Jun 24, 2027 8 months left

Related courses

See all

Other providers’ courses on the same topic

More from American College of Preventive Medicine

See all

This provider’s courses closest to this one